Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3797 - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Aafke Creemers

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

A. Creemers1, S.L. Meijer2, L. Holtzer3, M. Stoffels3, H. van Ooijen3, A.G.C. van Brussel3, E.M.G. Aussems-Custers3, M.I. van Berge Henegouwen4, M. Hulshof5, S.K. Krishnadath6, A. van de Stolpe3, M.F. Bijlsma7, H.W.M. van Laarhoven8

Author affiliations

  • 1 Medical Oncology/lexor, Amsterdam UMC, 1105AZ - Amsterdam/NL
  • 2 Pathology, Amsterdam UMC, University of Amsterdam, 1105 AZ - Amsterdam/NL
  • 3 Precision Diagnostics, Philips Research, 5656 AE - Eindhoven/NL
  • 4 Surgery, Amsterdam UMC, University of Amsterdam, 1105 AZ - Amsterdam/NL
  • 5 Radiotherapy, Amsterdam UMC, University of Amsterdam, 1105 AZ - Amsterdam/NL
  • 6 Gastroenterology, Amsterdam UMC, University of Amsterdam, 1105 AZ - Amsterdam/NL
  • 7 Lexor, Amsterdam UMC, 1105AZ - Amsterdam/NL
  • 8 Dept. Of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ - Amsterdam/NL
More

Resources

Abstract 3797

Background

To reveal candidate signaling pathways for targeted therapy in esophageal cancer (EC), and esophageal adenocarcinoma (EAC) in particular, we investigated key signal transduction pathways in material available in clinical routine, before and after neoadjuvant chemoradiation (nCRT), and for primary tumor and recurrent disease.

Methods

Paraffin-embedded material from three cohorts was used; (i) resectable EC; patients treated with an esophagectomy or receiving nCRT prior to resection, including cases with an available pre-nCRT biopsy of the primary tumor and corresponding resection; (ii) recurrent EC; patients of whom a resection and metachronous recurrence could be obtained. In addition, to explore the possibility to use patient-derived-xenografts (PDX) as a model to identify novel therapies, (iii) PDX of matched patient material was analyzed. Digitally annotated tumor areas ≥2 mm2 were transferred to a consecutive hematoxylin-stained slide and scraped for RNA extraction. Subsequently, a panel of qPCRs was performed, to infer signal transduction activity of the AR-, ER-, PI3K- (inverse of FOXO), HH-,TGF-β- and Wnt pathway.

Results

In pre-treatment EAC biopsies (i), high PI3K- and low TGF-β-pathway activity were correlated with poor pathological response. During treatment, a significant increase in PI3K- and decrease in TGF-β activity was observed in EAC poor nCRT responders compared to good responders (p = 0.003 and p = 0.042, respectively). Patients with a post-nCRT poor responder profile (high PI3K/ low TGF-β pathway activity) showed inferior disease free survival (median 17 vs. 97 months p = 0.055). Moreover, in nCRT treated patients, higher PI3K and lower TGF-β activities were seen in metachronous recurrences compared to resected tumors (ii) (p = 0.001 and p = 0.007, respectively). Pathway activity profiles were conserved between PDX and primary patient material (iii).

Conclusions

Loss of tumor-suppressive TGF-β and concurrent high PI3K pathway activity are associated with poor response to nCRT in EAC. This poor-responder profile is preserved in recurrences of nCRT pre-treated patients and PDX models, providing a valuable tool to experimentally test targeting candidate signal pathways such as PI3K.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Philips Research.

Funding

Philips Research.

Disclosure

L. Holtzer: Full / Part-time employment: Philips. M. Stoffels: Research grant / Funding (self), Full / Part-time employment: Philips. H. van Ooijen: Licensing / Royalties, Full / Part-time employment: Philips. A.G.C. van Brussel: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. E.M.G. Aussems-Custers: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. A. van de Stolpe: Licensing / Royalties, Full / Part-time employment: Philips. M.F. Bijlsma: Research grant / Funding (self): Celgene; Advisory / Consultancy: Servier. H.W.M. van Laarhoven: Advisory / Consultancy, Research grant / Funding (self): Celgene; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): Nordic; Advisory / Consultancy, Research grant / Funding (self): Lilly; Research grant / Funding (self): Merck Serono; Research grant / Funding (self): Bayer; Research grant / Funding (self): MSD; Research grant / Funding (self): Philips; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.